Sequence variation of the HVR1 region of hepatitis C virus in response to interferon-α and ribavirin treatment

Journal of Infection in Developing Countries

Volumn 5, Issue 5, 2011, Pages 370-376

  Al Qahtani, Ahmed A ^a,b   Rubino, Salvatore ^c   Al Ahdal, Mohammed N ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

HCV; HVR1; Non responder; Responder; Treatment

Indexed keywords

ALPHA INTERFERON; AMINO ACID; COMPLEMENTARY DNA; RIBAVIRIN; VIRUS RNA;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CLONE; CODON; CONTROLLED STUDY; DRUG RESPONSE; GENE LOCUS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERVARIABLE REGION 1; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SAUDI ARABIA; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS GENOME;

HEPATITIS C VIRUS;

EID: 79958158079     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.1806     Document Type: Article

References (37)

1. Ogata N, Alter HJ, Miller RH, Purcell RH (1991) Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88: 3392-3396.
2. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo Q-L, Houghton M, Kuo G (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6547-6549.
3. Di Bisceglie AM (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31: 1014-1018.
4. Steinhauer DA, Domingo E, Holland JJ (1992) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122: 281-288.
5. Smith DB, Simmonds P (1997) Characteristics of nucleotide substitution in the hepatitis C virus genome: constraints on sequence change in coding regions at both ends of the genome. J Mol Evol 45: 238-246.
6. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F (2007) Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 13: 2416-2426.
7. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, Chen TM, Hu TH, Chen WJ, Changchien CS (2003) Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 10: 87-94.
8. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, Walker CM, Grakoui A (2008) Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 4: e1000143.
9. Schinkel J, Spaan WJ, Kroes AC (2004) Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir Ther 9: 275-286.
10. Wohnsland A, Hofmann WP, Sarrazin C (2007) Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20: 23-38.
11. Gale M Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939-945.
12. Smith DB (1999) Evolution of the hypervariable region of hepatitis C virus. J Viral Hepat 6: 41-46.
13. Hino K, Korenaga M, Orito E, Katoh Y, Yamaguchi Y, Ren F, Kitase A, Satoh Y, Fujiwara D, Okita K (2002) Constrained genomic and conformational variability of the hypervariable region 1 of hepatitis C virus in chronically infected patients. J Viral Hepat 9: 194-201.
14. Alfonso V, Flichman DM, Sookoian S, Mbayed VA, Campos RH (2004) Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection. J Gen Virol 85: 39-46.
15. López-Labrador FX, Ampurdanès S, Giménez-Barcons M, Guilera M, Costa J, Jiménez de Anta MT, Sánchez-Tapias JM, Rodés J, Sáiz JC (1999) Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection (correction of interferon). Hepatology 29: 897-903.
16. Al-Faleh FZ, Aljumah A, Rezeig M, Al-Kanawi, Al-Otaibi M, Alahdal M, Al-Humayed S, Mayet I, Al-Juhani M, Al-Karawi M, George K, Sbeih F (2000) Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 7: 287-291.
17. Al-Ahdal MN, Rezeig MA, Kessie G (1997) Genotyping of hepatitis C virus isolates from Saudi patients by analysis of sequences from PCR-amplified core region of the virus genome. Ann Saudi Med 17: 601-604.
18. Al-Qahtani A, Kesie G, Al-Faleh F, Al-Ahdal A (2010) Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon and ribavirin therapy. Ann Saud Med 30: 109-114.
19. Timm J, Neukamm M, Kuntzen T, Kim AY, Chung RT, Brander C, Lauer GM, Walker BD, Allen TM (2007) Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat 14: 330-337.
20. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing the phylogenetic tree. Mol Biol Evol 4: 406-425.
21. Higgins DG, Bleasby AJ, Fuchs R (1992) Clustal V: Improved software for multiple sequence alignment. Comput Appl Biosci 8: 189-191.
22. Schinazi RF, Bassit L, Gavegnano C (2010) HCV drug discovery aimed at viral eradication. J Viral Hepat 17: 77-90.
23. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
24. Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25: 71-99.
25. Polyak SJ, Faulkner G, Carithers RL Jr, Corey L, Gretch DR (1997) Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 175: 1101-1107.
26. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26: 6-13.
27. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344.
28. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker CM (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895.
29. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Group. N Engl J Med 339: 1493-1499.
30. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Group. N Engl J Med 339: 1485-1492.
31. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C (1994) Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 75: 1361-1369.
32. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C (1995) Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22: 30-35.
33. Zeuzem S, Schmidt JM, Lee J-H, et al (1996) Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 23: 366-371.
34. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T (1994) Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20: 1121-1130.
35. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchison J, Houghton M (1992) Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 89: 3468-3472.
36. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 91: 7792-7796.
37. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, Yoshikura H (1996) A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 hepatitis C virus can prevent viral infection in cell cultures. Virology 223: 409-412.